Article

Neoadjuvant hormones: 8-months regimen appears to be no better than3-month regimen

Eight months of neoadjuvant hormone therapy prior to radiation therapyappears to offer no significant advantage over the standard of 3 monthsof therapy, at least in low- and intermediate-risk prostate cancer patients.

Related Videos
2 experts in this video
2 experts in this video
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.